The Effact of Helicobacter Hylori Eradication on the Development of Gastric Mucosa Pathology
The Effact of Helicobacter Hylori Eradication on the Development of Gastric Mucosa Pathology
Subjects who are included will recieve Hp eradication therapy based on antimicrobial
 susceptibility test. After the therapy, the subjects will be divided into two groups, the
 successful group and the failure group. And then they wiil be followed up to observe the
 development of the gastric mucosa pathology.
Subjects who are included will recieve Hp eradication therapy based on antimicrobial
 susceptibility test. After the therapy, the subjects will be divided into two groups, the
 successful group and the failure group. The subjects who fail to eradicate the Hp after
 initial treatment and rescue treatment will go into the failure group. Otherwhile, they will
 go to the successful group.And then they wiil be followed up to observe the development of
 the gastric mucosa pathology. For mild atrophy gastritis, non- intestinal metaplasial
 gastritis, follow-up is performed every 2-3 years.For severe atrophy gastritis, intestinal
 metaplasial gastritis, follow-up is performed every 1-2 years. For patients wth high-grade
 intraepithelial neoplasia, they can be included 3 months after the endoscopic treatment, and
 the follow up will be performed at 6, 12 months after the treatment and then the follow up
 will be carried out every 1 year. For non-atrophic gastritis, no follow-up will be performed.
 All included patients will recieve a follow-up at the endpoint of 5 years. The follow-up
 includes endoscopy examination and serum test of PG I,PG II and gastrin 17.
Inclusion Criteria:

 -  Patients, aged between 18 and 70 years old, with positive H. pylori infection that was
 not eradicated by previous therapies are included. The H. pylori infection is
 confirmed by the positive rapid urease test or 13C-breath test.

 Exclusion Criteria:

 -  Patients with significant underlying disease including liver, cardiac, pulmonary, and
 renal diseases, neoplasia, coagulopathy and genetic diseases, history of gastric
 surgery, pregnancy, breast-feeding, active gastrointestinal bleeding, patients with
 peptic ulcer, the use of PPI, NSAID or antibiotics during the 4 weeks prior to
 enrolment, and previous history of allergic reactions to any of the medications used
 in this protocol. Patients previously treated with H. pylori eradication regimens or
 those unwilling to participate in the study were also excluded.